Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity In Vivo

Michał Abram; Marcin Jakubiec; Katelyn Reeb; Mary Hongying Cheng; Robin Gedschold; Anna Rapacz; Szczepan Mogilski; Katarzyna Socała; Dorota Nieoczym; Małgorzata Szafarz; Gniewomir Latacz; Bartłomiej Szulczyk; Justyna Kalinowska‐Tłuścik; Kinga Gaweł; Camila V. Esguerra; Elżbieta Wyska; Christa E. Müller; İvet Bahar; Andréia C. K. Fontana; Piotr Właź; Rafał M. Kamiński; Krzysztof Kamiński

doi:10.1021/acs.jmedchem.2c00534

Abstract

] may be considered as the first-in-class small-molecule PAM of EAAT2 with potential for further preclinical and clinical development in epilepsy and possibly other CNS disorders.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abram et al. (2022) studied this question.

synapsesocial.com/papers/6a9a977a53362da04b0e58b8 https://doi.org/10.1021/acs.jmedchem.2c00534

View Full Paper

Ask AI

Bookmark

Share

Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity In Vivo

Abstract

Discussion

Cite This Study

Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity In Vivo

Abstract

Discussion

Cite This Study

Keep reading

Keep reading